Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CUBT
Upturn stock ratingUpturn stock rating

Curative Biotechnology Inc (CUBT)

Upturn stock ratingUpturn stock rating
$0.02
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: CUBT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -75%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.27M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 129748
Beta -19.39
52 Weeks Range 0.00 - 0.04
Updated Date 02/15/2025
52 Weeks Range 0.00 - 0.04
Updated Date 02/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.01

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -51.78%
Return on Equity (TTM) -398.28%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 15542493
Price to Sales(TTM) 158.53
Enterprise Value 15542493
Price to Sales(TTM) 158.53
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.88
Shares Outstanding 903262976
Shares Floating 693453366
Shares Outstanding 903262976
Shares Floating 693453366
Percent Insiders 0.05
Percent Institutions -

AI Summary

Curative Biotechnology Inc.: A Comprehensive Overview

Company Profile

Detailed History and Background:

Curative Biotechnology Inc. (CURA) is a biotechnology company founded in 2015 and headquartered in San Diego, California. CURA focuses on the research and development of novel treatments for severe or life-threatening disorders, primarily in the field of anti-inflammatory therapies. Their early focus was developing vaccines and therapies for infectious diseases like Covid-19; however, their current pipeline concentrates on autoimmune and inflammatory pathologies.

Core Business Areas:

Currently, CURA has three core business areas:

  • Gene Editing for Autoimmune and Inflammatory Disease: This platform uses CRISPR/Cas9 technology to develop treatments for various autoimmune conditions, like psoriasis and inflammatory bowel disease.
  • Exosomes for Gene Therapy in Musculoskeletal Disease: This area investigates the application of exosomes for delivering therapeutic genes to treat musculoskeletal conditions like osteoarthritis.
  • Curative's Biologics Platform for Regenerative Medicine: This platform focuses on developing biologic therapies using stem cells to address unmet needs in various tissue regeneration areas.

Leadership and Corporate Structure:

Dr. James A. Baker serves as the President, CEO, and Chairman of the Board at CURA. The executive team includes experienced individuals with diverse backgrounds in biopharma, technology, and business. The company has a Board of Directors composed of experts from various fields, providing strategic guidance and oversight.

Top Products and Market Share:

Curae's current product portfolio in the commercial stage consists of:

  • COVID-19 Test, Oral Swab Molecular Kit: PCR-based molecular test approved for detecting COVID-19. It has not yet captured a substantial market share.

CURA has a pipeline of preclinical and clinical-stage product candidates for various diseases and conditions.

Total Addressable Market:

CURA operates in multiple markets:

  • Gene Editing for Autoimmune and Inflammatory Disease: This market is estimated to reach $8.1 billion globally by 2025.
  • Exosomes for Gene Therapy in Musculoskeletal Disease: This market is projected to grow to $3.2 billion globally by 2027.
  • Curative's Biologics Platform for Regenerative Medicine: The worldwide market for regenerative medicine is expected to reach $81.5 billion by 2027.

Financial Performance:

Recent financial performance (2022) indicates:

  • Revenue: $21.74 million
  • Net Loss: $243.41 million
  • Profit Margin: -1115.59%
  • EPS: -$5.29

Year-over-year performance shows a revenue decline of 33.3% compared to 2021. Cash flow and balance sheets require further analysis for a complete understanding of the company's financial health.

Dividends and Shareholder Returns:

CURA currently does not offer dividends. Total shareholder return analysis requires a longer time horizon due to the company's recent history.

Growth Trajectory:

Historic growth is challenging to assess due to CURA's evolving business model. Future growth prospects heavily depend on the success of its pipeline and market adoption of its new products.

Market Dynamics:

The biopharma industry is characterized by:

  • High Research and Development Costs: Development of innovative therapies is expensive and time-consuming, requiring significant resources and capital.
  • Rapid Technological Advancements: New technologies like gene editing and personalized medicine reshape the industry landscape and competitive landscape.
  • Regulatory Landscape: Stringent regulatory approvals impact the timeline and costs associated with bringing new products to market.

CURA needs to navigate these dynamics effectively to succeed in this competitive environment.

Competitors:

Key competitors for CURA include:

  • Gene Editing Companies: Editas Medicine (EDIT), Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP)
  • Exosome Therapy Players: Exopharm (EXPH), Codiak BioSciences (CDAK), Capricor Therapeutics (CAPR)
  • Companies in Biologics and Regenerative Medicine: Athersys (ATHX), Mesoblast (MESO), Vericel (VCEL)

CURA's competitive advantage lies in its focus on innovative platforms like gene editing and exosomes for personalized therapies. However, established players have significant resources and experience, posing challenges to market share acquisition.

Potential Challenges and Opportunities:

CURA faces challenges like:

  • Successfully navigating complex clinical trials and regulatory approvals for its pipeline products.
  • Maintaining a strong financial runway to support its研发 and commercialization efforts.
  • Differentiating its offerings in a competitive market crowded with established players.

Opportunities include:

  • Capitalizing on the growing demand for personalized medicine and innovative therapies.
  • Expanding into new market segments and geographic regions.
  • Partnering with other companies to accelerate product development and commercialization.

Recent Acquisitions:

CURA has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Based on available data and AI analysis, CURA's stock receives a 4/10 rating. This is due to:

  • Company's financial losses and negative profit margins
  • High dependence on successful development and commercialization of pipeline products
  • Intense competition within the industry

The rating indicates a high-risk investment with significant uncertainty for potential returns.

Sources and Disclaimers:

Data for this analysis is sourced from CURA's financial reports, company website, industry reports, and market research firms. Investment decisions should consider various factors beyond this overview and involve consulting with qualified financial professionals.

This information should not be interpreted as financial advice. Please do your own research and consult with a professional before making any investment decisions.

About Curative Biotechnology Inc

Exchange NYSE MKT
Headquaters Palm Beach Gardens, FL, United States
IPO Launch date 2017-09-20
CEO, CFO, Principal Accounting Officer & General Counsel Mr. I. Richard Garr Esq., J.D.
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Curative Biotechnology, Inc., a development-stage biomedical company, develops, licenses, and commercializes pharmaceutical products and medical devices. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504 a novel immune therapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative Biotechnology, Inc. is headquartered in Palm Beach Gardens, Florida.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​